Cited by 117PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase SignalingRNA and protein synthesis mechanisms

Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases

Open access
Liu, Rui, Proud, Christopher G·2016·Acta Pharmacologica Sinica

Abstract

Eukaryotic elongation factor 2 kinase (eEF2K) is an unusual protein kinase that regulates the elongation stage of protein synthesis by phosphorylating and inhibiting its only known substrate, eEF2. Elongation is a highly energy-consuming process, and eEF2K activity is tightly regulated by several signaling pathways. Regulating translation elongation can modulate the cellular energy demand and may also control the expression of specific proteins. Growing evidence links eEF2K to a range of human diseases, including cardiovascular conditions (atherosclerosis, via macrophage survival) and pulmonary arterial hypertension, as well as solid tumors, where eEF2K appears to play contrasting roles depending on tumor type and stage. eEF2K is also involved in neurological disorders and may be a valuable target in treating depression and certain neurodegenerative diseases. Because eEF2K is not required for mammalian development or cell viability, inhibiting its function may not elicit serious side effects, while the fact that it is an atypical kinase and quite distinct from the vast majority of other mammalian kinases suggests the possibility to develop it into compounds that inhibit eEF2K without affecting other important protein kinases. Further research is needed to explore these possibilities and there is an urgent need to identify and characterize potent and specific small-molecule inhibitors of eEF2K. In this article we review the recent evidence concerning the role of eEF2K in human diseases as well as the progress in developing small-molecule inhibitors of this enzyme.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/aps.2015.123

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • eEF2K signaling intersects with excitation-inhibition balance and circuit-level plasticity, suggesting strong synergy with circuit-specific interventions.

    “eEF2K signaling intersects with excitation inhibition balance and circuit level plasticity, suggesting strong synergy with circuit specific interventions [159,160,164].”

    From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [160]

    The “Neurological roles of eEF2K” section links eEF2K to synaptic plasticity, altered brain activation in mutant mice, and a neuronal response to a GABA-receptor antagonist (page unavailable in our copy). It does not establish an effect on excitation–inhibition balance or discuss synergy with circuit-specific interventions; the latter appears to be the citing authors’ inference. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • All available eEF2K compounds remain experimental, with unresolved issues in kinase selectivity, brain exposure, and chronic tolerability.

    “Despite consistent neuroprotective- and plasticity-enhancing effects across preclinical disease models, all available compounds remain experimental, with unresolved issues in kinase selectivity, brain exposure, and chronic tolerability [159,160,161].”

    From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [160]

    The “Inhibitors of eEF2K” section describes selectivity and cellular-effectiveness problems, and the Conclusion calls for better inhibitors for preclinical studies. These passages support the compounds’ experimental status, but our copy does not assess brain exposure or chronic tolerability. Page numbers were not supplied. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Browne GJ, Proud CG. A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol 2004; 24: 2986-97.

Cited by

Sorted by citations

Authors
Liu, R., & Proud, C. G.
Affiliations
South Australian Health and Medical Research Institute (AU)
Corresponding author
Proud, Christopher G
Venue
Acta Pharmacologica Sinica
Published
2016-01-25
Volume
37
Issue
3
Pages
285-294
ISSN
  • 0253-9756 (ISSN-L)
  • 1671-4083
  • 1745-7254
OpenAlex
W2410758979
Cited by
117
References
66
Citations by year
2026: 11 · 2025: 22 · 2024: 10 · 2023: 14 · 2022: 12 · 2021: 16 · 2020: 11 · 2019: 6 · 2018: 5 · 2017: 5 · 2016: 5
FWCI
0.63
Type
journal article
Language
en
Open access
Locations
  • Acta Pharmacologica Sinica (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
Keywords
eEF2K, eEF2 phosphorylation, translation elongation, protein kinase inhibitors, small molecule inhibitors, cancer, cardiovascular disease, atherosclerosis, pulmonary arterial hypertension, neurodegenerative diseases, depression, therapeutic target
MeSH terms
Animals, Cardiovascular Diseases, Humans, Neoplasms, Neurodegenerative Diseases, Protein Kinase Inhibitors, Elongation Factor 2 Kinase, Drug Discovery, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review